Novartis Ag (NVS) Cash & Equivalents (2009 - 2026)

Novartis Ag has reported Cash & Equivalents for 18 years, with the latest figure at $7.6 billion in Q2 2026.

• Quarterly Cash & Equivalents rose 14.42% year-over-year to $7.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.6 billion (up 14.42% YoY) and the FY2025 annual result came in at $11.4 billion, changed 0.21% from the prior year.
• Cash & Equivalents climbed to $7.6 billion in Q2 2026 per NVS's latest filing, from $6.9 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $13.9 billion in Q1 2022 and troughed at -$88.0 million in Q3 2022.
• A 5-year average of $7.5 billion and a median of $7.6 billion in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 780.0% in 2022, then soared 12130.34% in 2023.
• Over 5 years, Cash & Equivalents stood at $7.5 billion in 2022, then jumped by 78.17% to $13.4 billion in 2023, then slipped by 14.44% to $11.5 billion in 2024, then fell by 0.21% to $11.4 billion in 2025, then sank by 33.4% to $7.6 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.6 billion, $6.9 billion, and $11.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.